Paclitaxel oral - DAE HWA Pharmaceutical
Alternative Names: DHP-107; Liporaxel; RMX-3001Latest Information Update: 28 Aug 2024
At a glance
- Originator DAE HWA Pharmaceutical
- Developer DAE HWA Pharmaceutical; HaiHe Biopharma
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Gastric cancer
- Phase III Breast cancer
- Phase I Solid tumours
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Hungary (PO)
- 12 Dec 2022 Daehwa Pharmaceutical initiates enrolment in a phase I trial for Solid tumours(Late-stage disease) in Hungary (NCT04675528)(EudraCT2020-004976-16)
- 14 Sep 2022 Phase-III clinical trials in Breast cancer in Eastern Europe, South Korea (PO) (HaiHe Biopharma pipeline, September 2022)